2025
Cerebrospinal fluid and brain positron emission tomography measures of synaptic vesicle glycoprotein 2A: Biomarkers of synaptic density in Alzheimer's disease
Mecca A, Ashton N, Chen M, O'Dell R, Toyonaga T, Zhao W, Young J, Salardini E, Bates K, Ra J, Goodcase S, Silva‐Rudberg J, Nabulsi N, Brinkmalm A, Kvartsberg H, Schöll M, Nilsson J, Arnsten A, Huang Y, Hansson O, Zetterberg H, Carson R, Blennow K, van Dyck C. Cerebrospinal fluid and brain positron emission tomography measures of synaptic vesicle glycoprotein 2A: Biomarkers of synaptic density in Alzheimer's disease. Alzheimer's & Dementia 2025, 21: e70344. PMID: 40491249, PMCID: PMC12149441, DOI: 10.1002/alz.70344.Peer-Reviewed Original ResearchConceptsSynaptic vesicle glycoprotein 2APositron emission tomographyAlzheimer's diseaseSynaptic densityEnzyme-linked immunosorbent assayC]UCB-J positron emission tomographyPositron emission tomography measurementsEmission tomographyAxonal proteinsCN participantsImmunosorbent assaySymptomatic Alzheimer's diseaseAD groupProteinAssayParticipantsSV2AAlzheimerCerebrospinal fluidBrainInvestigate associationsCerebrospinal fluid assaysSV2A positron emission tomographySex differences in the confounders influencing the relationships linking socioeconomic factors and cognitive performance with family history of Alzheimer's disease and related dementias
He J, Cabrera‐Mendoza B, Friligkou E, Mecca A, van Dyck C, Pathak G, Polimanti R. Sex differences in the confounders influencing the relationships linking socioeconomic factors and cognitive performance with family history of Alzheimer's disease and related dementias. Alzheimer's & Dementia 2025, 21: e70215. PMID: 40421744, PMCID: PMC12107445, DOI: 10.1002/alz.70215.Peer-Reviewed Original ResearchConceptsSocioeconomic factorsFamily historySocioeconomic statusFamily history of Alzheimer's diseaseAssociation of socioeconomic factorsHistory of Alzheimer's diseaseUs Research ProgramCognitive performanceHigher socioeconomic statusSex-specific associationsAlzheimer's disease assessmentSex differencesUK BiobankADRDAlzheimer's diseaseGenetically informed analysesDementiaSample sizeSexGenetic analysisAlzheimerLimited informationStatusConfoundingBiobank0074 The Relationship of Sleep Disorder History with Gray Matter BOLD-CSF Coupling Among Persons at Risk for and with Alzheimer’s Disease
Cho G, Liu X, Mecca A, Miner B. 0074 The Relationship of Sleep Disorder History with Gray Matter BOLD-CSF Coupling Among Persons at Risk for and with Alzheimer’s Disease. Sleep 2025, 48: a34-a34. DOI: 10.1093/sleep/zsaf090.0074.Peer-Reviewed Original ResearchAssessment of the relationship between synaptic density and metabotropic glutamate receptors in early Alzheimer’s disease: a multi-tracer PET study
Salardini E, O’Dell R, Tchorz E, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of the relationship between synaptic density and metabotropic glutamate receptors in early Alzheimer’s disease: a multi-tracer PET study. Alzheimer's Research & Therapy 2025, 17: 98. PMID: 40329311, PMCID: PMC12054321, DOI: 10.1186/s13195-025-01739-1.Peer-Reviewed Original ResearchConceptsDistribution volume ratioMedial temporal lobePositron emission tomographyTemporal lobeSynaptic densityMetabotropic glutamate receptor subtype 5Multi-tracer PET studiesAlzheimer's diseaseCerebellum reference regionAmyloid-positive participantsSynaptic lossSynaptic vesicle glycoprotein 2AMetabotropic glutamate receptorsPositron emission tomography scanNeocortical regionsSubtype 5MGluR5Entorhinal cortexAD groupReference regionGlutamate receptorsExploratory analysisWidespread reductionsLongitudinal studyReceptor bindingCerebrospinal Fluid Biomarkers and Cognition in Alzheimer Disease and Frontotemporal Dementia in a Memory Clinic Setting
Cayir S, Sadabad F, Mecca A, Matuskey D, Fesharaki-Zadeh A. Cerebrospinal Fluid Biomarkers and Cognition in Alzheimer Disease and Frontotemporal Dementia in a Memory Clinic Setting. Alzheimer Disease & Associated Disorders 2025, 39: 22-27. PMID: 40397510, DOI: 10.1097/wad.0000000000000656.Peer-Reviewed Original ResearchMoCA scoresMemory clinic settingHospital memory clinicCognitive performanceMontreal Cognitive AssessmentFrontotemporal dementiaAlzheimer's diseaseCognitive test scoresP-tauMemory clinicElectronic records of patientsRetrospective cohort studyT-tauCohort studyCognitive AssessmentElectronic recordsMoCACerebrospinal fluidRecords of patientsIndex scoreTau-related pathologyClinical settingDementiaConcentrations of T-tauScores
2024
Lower slow wave sleep and rapid eye‐movement sleep are associated with brain atrophy of AD‐vulnerable regions
Cho G, Mecca A, Buxton O, Liu X, Miner B. Lower slow wave sleep and rapid eye‐movement sleep are associated with brain atrophy of AD‐vulnerable regions. Alzheimer's & Dementia 2024, 20: e093827. PMCID: PMC11713325, DOI: 10.1002/alz.093827.Peer-Reviewed Original ResearchInferior parietal regionsSlow wave sleepAD-vulnerable regionsAssociated with smaller volumesParietal regionsPresence of cerebral microbleedsSleep architectureAlzheimer's diseaseCerebral microbleedsIncreased risk of Alzheimer's diseaseProportion of timeRisk of Alzheimer's diseaseBaseline cognitive functionLobar cerebral microbleedsModifiable risk factorsAssociated with lower volumesAssociated with brain atrophyBaseline sleep architectureSleep architecture variablesSleep deficiencyAssociated with ADFalse discovery rateAtherosclerosis RiskAD pathogenesisEye-movement sleepLower slow wave sleep and rapid eye‐movement sleep are associated with brain atrophy of AD‐vulnerable regions
Cho G, Mecca A, Buxton O, Liu X, Miner B. Lower slow wave sleep and rapid eye‐movement sleep are associated with brain atrophy of AD‐vulnerable regions. Alzheimer's & Dementia 2024, 20: e089369. PMCID: PMC11716384, DOI: 10.1002/alz.089369.Peer-Reviewed Original ResearchInferior parietal regionsSlow wave sleepAD-vulnerable regionsAssociated with smaller volumesParietal regionsPresence of cerebral microbleedsSleep architectureAlzheimer's diseaseCerebral microbleedsIncreased risk of Alzheimer's diseaseProportion of timeRisk of Alzheimer's diseaseBaseline cognitive functionLobar cerebral microbleedsModifiable risk factorsAssociated with lower volumesAssociated with brain atrophyBaseline sleep architectureSleep architecture variablesSleep deficiencyAssociated with ADFalse discovery rateAtherosclerosis RiskAD pathogenesisEye-movement sleepConnectivity as a universal predictor of tau spreading in typical and atypical Alzheimer’s disease
de Bruin H, Groot C, ADNI, Barthel H, Bischof G, Boellaard R, Brendel M, Cash D, Coath W, Day G, Dickerson B, Doering E, Drzezga A, van Dyck C, van Eimeren T, van der Flier W, Fredericks C, Fryer T, van de Giessen E, Gordon B, Graff‐Radford J, Hobbs D, Höglinger G, Hönig M, Irwin D, Jones P, Josephs K, Katsumi Y, Lee E, Levin J, Malpetti M, McGinnis S, Mecca A, Nasrallah I, O'Brien J, O'Dell R, Palleis C, Perneczky R, Phillips J, Pijnenburg Y, Putcha D, Rahmouni N, Rosa‐Neto P, Rowe J, Rullmann M, Sabri O, Saur D, Schildan A, Schott J, Schroeter M, Servaes S, Sintini I, Stevenson J, Therriault J, Touroutoglou A, Trainer A, Visser D, Weston P, Whitwell J, Wolk D, Franzmeier N, Ossenkoppele R. Connectivity as a universal predictor of tau spreading in typical and atypical Alzheimer’s disease. Alzheimer's & Dementia 2024, 20: e093663. PMCID: PMC11713789, DOI: 10.1002/alz.093663.Peer-Reviewed Original ResearchAlzheimer's diseaseTau spreadingProgression of Alzheimer's diseaseTau-PETFunctional proximityPosterior patterningAD variantsTauPersonalized medicineTau-PET standardized uptake value ratiosVariantsWidespread patternAtypical ADDominant patternAtypical Alzheimer's diseaseRegionNeurodegenerationPatternsConnectivity as a universal predictor of tau spreading in typical and atypical Alzheimer’s disease
de Bruin H, Groot C, ADNI, Barthel H, Bischof G, Boellaard R, Brendel M, Cash D, Coath W, Day G, Dickerson B, Doering E, Drzezga A, van Dyck C, van Eimeren T, van der Flier W, Fredericks C, Fryer T, van de Giessen E, Gordon B, Graff‐Radford J, Hobbs D, Höglinger G, Hönig M, Irwin D, Jones P, Josephs K, Katsumi Y, Lee E, Levin J, Malpetti M, McGinnis S, Mecca A, Nasrallah I, O'Brien J, O'Dell R, Palleis C, Perneczky R, Phillips J, Pijnenburg Y, Putcha D, Rahmouni N, Rosa‐Neto P, Rowe J, Rullmann M, Sabri O, Saur D, Schildan A, Schott J, Schroeter M, Servaes S, Sintini I, Stevenson J, Therriault J, Touroutoglou A, Trainer A, Visser D, Weston P, Whitwell J, Wolk D, Franzmeier N, Ossenkoppele R. Connectivity as a universal predictor of tau spreading in typical and atypical Alzheimer’s disease. Alzheimer's & Dementia 2024, 20: e085869. PMCID: PMC11714601, DOI: 10.1002/alz.085869.Peer-Reviewed Original ResearchAlzheimer's diseaseTau spreadingProgression of Alzheimer's diseaseTau-PETFunctional proximityPosterior patterningAD variantsTauPersonalized medicineTau-PET standardized uptake value ratiosVariantsWidespread patternAtypical ADDominant patternAtypical Alzheimer's diseaseRegionNeurodegenerationPositive probabilityPatternsValidation of a Simplified Tissue-to-Reference Ratio Measurement Using SUVR to Assess Synaptic Density Alterations in Alzheimer Disease with [11C]UCB-J PET
Young J, O’Dell R, Naganawa M, Toyonaga T, Chen M, Nabulsi N, Huang Y, Cooper E, Miller A, Lam J, Bates K, Ruan A, Nelsen K, Salardini E, Carson R, van Dyck C, Mecca A. Validation of a Simplified Tissue-to-Reference Ratio Measurement Using SUVR to Assess Synaptic Density Alterations in Alzheimer Disease with [11C]UCB-J PET. Journal Of Nuclear Medicine 2024, 65: jnumed.124.267419. PMID: 39299782, PMCID: PMC11533916, DOI: 10.2967/jnumed.124.267419.Peer-Reviewed Original ResearchDistribution volume ratioSUV ratioSynaptic densityEffect sizeAlzheimer's diseaseLongitudinal study of Alzheimer's diseaseMethods:</b> ParticipantsLongitudinal studyMeasure synaptic densityAD participantsStudy of Alzheimer's diseaseNormal cognitionReference regionOlder adultsMulticenterDensity alterationsDiffusion Imaging of Gray Matter Microstructure in Alzheimer’s Disease
Silva-Rudberg J, Mecca A. Diffusion Imaging of Gray Matter Microstructure in Alzheimer’s Disease. Journal Of Alzheimer’s Disease 2024, 101: 437-439. PMID: 39213077, DOI: 10.3233/jad-240673.Peer-Reviewed Original ResearchCT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease
Lizama B, Williams C, North H, Pandey K, Duong D, Di V, Mecca A, Blennow K, Zetterberg H, Levey A, Grundman M, van Dyck C, Caggiano A, Seyfried N, Hamby M. CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease. Alzheimer's & Dementia 2024, 20: 6860-6880. PMID: 39166791, PMCID: PMC11485314, DOI: 10.1002/alz.14152.Peer-Reviewed Original ResearchVolumetric magnetic resonance imagingMagnetic resonance imagingPharmacodynamic biomarkersMeta-analysisClinical developmentCerebrospinal fluidPhase 2 clinical trialResonance imagingAlzheimer's diseaseMechanism of actionClinical trialsTandem mass tag-mass spectrometryClinical cohortMild to moderate ADCandidate biomarkersCT1812CohortBiomarker signaturesBiomarkersProteomic findingsUnbiased analysisNetwork analysisAmyloid-betaSynaptic biologyBiological impactSynaptic density patterns in early Alzheimer’s disease assessed by independent component analysis
Fang X, Raval N, O’Dell R, Naganawa M, Mecca A, Chen M, van Dyck C, Carson R. Synaptic density patterns in early Alzheimer’s disease assessed by independent component analysis. Brain Communications 2024, 6: fcae107. PMID: 38601916, PMCID: PMC11004947, DOI: 10.1093/braincomms/fcae107.Peer-Reviewed Original ResearchMedial temporal brain regionsAlzheimer's diseaseTemporal brain regionsCognitive deficitsBrain regionsCognitive impairmentPostmortem studiesBinds to SV2ASynaptic densityReduction of synaptic densityIndependent component analysisSynaptic lossAlzheimerDeficitsImpairmentBrainNeocortexComponent analysisPrimary pathologySV2AA pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease
van Dyck C, Mecca A, O’Dell R, Bartlett H, Diepenbrock N, Huang Y, Hamby M, Grundman M, Catalano S, Caggiano A, Carson R. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease. Alzheimer's Research & Therapy 2024, 16: 20. PMID: 38273408, PMCID: PMC10809445, DOI: 10.1186/s13195-024-01382-2.Peer-Reviewed Original ResearchConceptsMild to moderate dementiaPositron emission tomographyAlzheimer's diseaseVolumetric MRIModerate dementiaClinical rating scalesSynaptic vesicle glycoprotein 2ACerebrospinal fluidMouse model of ADPharmacodynamic effectsPlacebo-controlled phase 1 clinical trialBiomarkers of AD pathologyClinical trialsCognitive measuresNominally significant differencesPhase 1 clinical trialModel of ADHippocampal cortexPhase 1/2 studyRating ScaleParallel-group trialSynaptic densityTrial registrationThe clinical trialPlacebo-controlledSigma-2 receptor ligands
2023
Tau epicenter identification and connectivity in clinically heterogeneous Alzheimer’s disease variants
Trainer A, Xu W, Chase A, O'Dell R, Tun S, Li J, Ju S, van Dyck C, Mecca A, Fredricks C. Tau epicenter identification and connectivity in clinically heterogeneous Alzheimer’s disease variants. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.079435.Peer-Reviewed Original ResearchAmnestic Alzheimer's diseaseLogopenic variant primary progressive aphasiaPosterior cortical atrophyFunctional connectivity mapsHigher tau burdenFunctional connectivityTau burdenAlzheimer's diseaseConnectivity mapsLongitudinal tau-PETSpread of tauVariant primary progressive aphasiaFusiform gyrusFrontal eye fieldPrimary progressive aphasiaBrains of participantsTau PET scansSuperior parietal lobulePatient-specific biomarkersCortical atrophyCommon subtypeTau-PETHealthy controlsParietooccipital cortexPET scansAging gene signature of memory CD8+ T cells is associated with neurocognitive functioning in Alzheimer’s disease
Young J, Park H, Kim M, Par-Young J, Bartlett H, Kim H, Unlu S, Osmani L, Shin M, Bucala R, van Dyck C, Allore H, Mecca A, You S, Kang I. Aging gene signature of memory CD8+ T cells is associated with neurocognitive functioning in Alzheimer’s disease. Immunity & Ageing 2023, 20: 71. PMID: 38042785, PMCID: PMC10693128, DOI: 10.1186/s12979-023-00396-y.Peer-Reviewed Original ResearchPeripheral bloodT cellsAlzheimer's diseaseEM CD8Memory CD8Gene signatureAge-related immune changesIL-7 receptor alphaEffector memory CD8Strong risk factorT cell expansionAD genesAge-associated expansionImmune changesRisk factorsCD8Dementia patientsIL-7RNeuropsychological testingReceptor alphaNeurocognitive functionRT-qPCR resultsDisease severityPatientsNormal personsAssessment of Gray Matter Microstructure and Synaptic Density in Alzheimer's Disease: A Multimodal Imaging Study With DTI and SV2A PET
Silva-Rudberg J, Salardini E, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Varma P, Toyonaga T, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of Gray Matter Microstructure and Synaptic Density in Alzheimer's Disease: A Multimodal Imaging Study With DTI and SV2A PET. American Journal Of Geriatric Psychiatry 2023, 32: 17-28. PMID: 37673749, PMCID: PMC10840732, DOI: 10.1016/j.jagp.2023.08.002.Peer-Reviewed Original ResearchSynaptic densityAlzheimer's diseaseMean diffusivitySynaptic lossGray matter microstructureGray matter mean diffusivityDisease pathologyHippocampal synaptic densityMajor pathological correlateSetting of ADAD-related neuropathologySynaptic vesicle glycoprotein 2AHippocampal mean diffusivityAlzheimer's disease pathologyAmyloid-positive participantsMatter mean diffusivityPositron emission tomography (PET) imagingEmission Tomography ImagingGray matter structuresPathological correlatesPositive participantsInverse associationAD groupCognitive impairmentDiseasePrincipal component analysis of synaptic density measured with [11C]UCB-J PET in early Alzheimer’s disease
O'Dell R, Higgins-Chen A, Gupta D, Chen M, Naganawa M, Toyonaga T, Lu Y, Ni G, Chupak A, Zhao W, Salardini E, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C, Mecca A. Principal component analysis of synaptic density measured with [11C]UCB-J PET in early Alzheimer’s disease. NeuroImage Clinical 2023, 39: 103457. PMID: 37422964, PMCID: PMC10338149, DOI: 10.1016/j.nicl.2023.103457.Peer-Reviewed Original ResearchConceptsCognitive domainsCognitive performanceSubjects' scoresCortical regionsNeuropsychological batteryEarly Alzheimer's diseaseAD groupBilateral regionsNormal participantsNegative loadingsCognitive impairmentCN participantsAlzheimer's diseaseParticipantsStructural correlatesStrong contributionParticipant characteristicsScoresPositive loadingsData-driven approachTotal variancePrincipal component analysisSpecific spatial patterns
2021
Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimer’s disease: A tracer kinetic modeling study
Chen MK, Mecca AP, Naganawa M, Gallezot JD, Toyonaga T, Mondal J, Finnema SJ, Lin SF, O’Dell R, McDonald JW, Michalak HR, Vander Wyk B, Nabulsi NB, Huang Y, Arnsten AF, van Dyck CH, Carson RE. Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimer’s disease: A tracer kinetic modeling study. Cerebrovascular And Brain Metabolism Reviews 2021, 41: 2395-2409. PMID: 33757318, PMCID: PMC8393289, DOI: 10.1177/0271678x211004312.Peer-Reviewed Original ResearchConceptsSynaptic densityMedial temporal regionsAlzheimer's diseaseNeocortical regionsTemporal regionsRelative outcome measuresMedial temporal lobeVivo PET imagingJ bindingOutcome measuresTemporal lobeMagnitude of reductionCN participantsBrain regionsAD participantsDiseasePET imagingConcordant reductionNormal participantsSynaptic vesiclesPerfusionMetabolismSuitable markerParticipantsSimilar patternAssociation of Aβ deposition and regional synaptic density in early Alzheimer’s disease: a PET imaging study with [11C]UCB-J
O’Dell R, Mecca AP, Chen MK, Naganawa M, Toyonaga T, Lu Y, Godek TA, Harris JE, Bartlett HH, Banks ER, Kominek VL, Zhao W, Nabulsi NB, Ropchan J, Ye Y, Vander Wyk BC, Huang Y, Arnsten AFT, Carson RE, van Dyck CH. Association of Aβ deposition and regional synaptic density in early Alzheimer’s disease: a PET imaging study with [11C]UCB-J. Alzheimer's Research & Therapy 2021, 13: 11. PMID: 33402201, PMCID: PMC7786921, DOI: 10.1186/s13195-020-00742-y.Peer-Reviewed Original ResearchConceptsRegional Aβ depositionAβ depositionEarly Alzheimer's diseaseSynaptic lossSynaptic densityAlzheimer's diseaseDistribution volume ratioPositron emission tomographyHippocampal synaptic densityMild AD dementiaDeposition of AβSignificant inverse associationAmnestic mild cognitive impairmentWhole-brain analysisMild cognitive impairmentCerebellar reference regionPET imaging studiesPlaque burdenAD dementiaInverse associationPostmortem studiesClinical severityNeurodegenerative processesClinical diseaseLarge cohort
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply